B.R.A.I.N. Biotechnology Research and Information Network AG Just Released Its Full-Year Results And Analysts Are Updating Their Estimates – Yahoo…

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) just released its yearly report and things are looking bullish. Results overall were solid, with revenues arriving 9.7% better than analyst forecasts at 40m. Higher revenues also resulted in substantially lower statutory losses which, at 0.58 per share, were 9.7% smaller than analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what top analysts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what analysts' statutory forecasts suggest is in store for next year.

Check out our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

XTRA:BNN Past and Future Earnings, January 18th 2020

Following the latest results, B.R.A.I.N. Biotechnology Research and Information Network's four analysts are now forecasting revenues of 43.5m in 2020. This would be a solid 8.6% improvement in sales compared to the last 12 months. Per-share statutory losses are expected to see a sharp uptick, reaching 0.47. Before this earnings announcement, analysts had been forecasting revenues of 40.0m and losses of 0.29 per share in 2020. While next year's revenue estimates increased, there was also a large cut to EPS expectations, suggesting the consensus has a bit of a mixed view of these results.

There was no major change to the consensus price target of 17.80, with growing revenues seemingly enough to offset the concern of growing losses. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on B.R.A.I.N. Biotechnology Research and Information Network, with the most bullish analyst valuing it at 24.00 and the most bearish at 9.50 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Zooming out to look at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up both against past performance, and against industry growth estimates. We would highlight that B.R.A.I.N. Biotechnology Research and Information Network's revenue growth is expected to slow, with forecast 8.6% increase next year well below the historical 15%p.a. growth over the last five years. By way of comparison, other companies in this market with analyst coverage, are forecast to grow their revenue at 3.8% next year. So it's pretty clear that, while B.R.A.I.N. Biotechnology Research and Information Network's revenue growth is expected to slow, it's still expected to grow faster than the market itself.

Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider market. The consensus price target held steady at 17.80, with the latest estimates not enough to have an impact on analysts' estimated valuations.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for B.R.A.I.N. Biotechnology Research and Information Network going out to 2024, and you can see them free on our platform here.

Story continues

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read the original post:
B.R.A.I.N. Biotechnology Research and Information Network AG Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo...

Global Biotechnology Congress 2017 – Student Registration: Boston … – Business Wire (press release)

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Biotechnology Congress 2017 - (5th in the Series) Student" conference to their offering.

The 'Global Biotechnology Congress 2017' would provide eminent scientists the opportunity to present their cutting edge researches in the field of biotechnology and its applications in medicine. A number of Nobel Laureates and leading researchers are expected to participate in this important conference.

This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Many Nobel Laureates and world's renowned experts will participate in the conference.

The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include major research advances in biotechnology, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research.

Throughout the course of the four day conference, you will have the opportunity to both network and hear leaders from the international academic and corporate biotechnology communities.

Benefits of Attending

- Exchange ideas and network with leading biotechnologists and decision makers.

- Bring together top international biotechnology professionals presenting cutting-edge discoveries, research and opportunities for new biotech business practices and partnerships.

- Participants can gain direct access to a core audience of biotechnology professionals and decision makers, and have increased visibility through branding and networking at the conference.

- Obtain a global roundup of Pharmaceutical research capabilities and opportunities.

- The conference will feature a commercial exhibition and poster sessions.

For more information about this conference visit http://www.researchandmarkets.com/research/3859jd/global

Visit link:
Global Biotechnology Congress 2017 - Student Registration: Boston ... - Business Wire (press release)

Why Puma Biotechnology Inc Jumped Higher Today – Motley Fool

Documents from the FDA suggest the agency is open to the possibility of approving neratinib. What happened

Shares ofPuma Biotechnology(NASDAQ:PBYI) are up 44% at 12:12 p.m., having been up as much as 84% today, as investors digest the Food and Drug Administration documentsposted ahead of Wednesday's advisory committee meeting to review the approvability of Puma's breast cancer drug neratinib.

Today's jump wasn't because of surprisingly good data but rather a relative lack of negative opinions of neratinib by the FDA reviewers.

Puma Biotechnology is trying to get neratinib approved as an extended treatment for breast cancer after the patient has received surgery followed by Herceptin and chemotherapy. The clinical trial showed that adding neratinib to that standard of care decreased the reoccurrence of breast cancer compared to placebo after a year of treatment with neratinib. But the drug causes severe diarrhea in many patients, which leads to patients reducing the dose or stopping the drug altogether.

Good efficacy with poor tolerability has led investors to worry about the approvability of the drug. The company'snegotiatingwith the FDA over which patients to include in the analysis didn't help, although that issue appears to be mostlyworked out. Today's review was fairly neutral, with the documents for the advisory committee noting that the efficacy analysis was basically the same using either set of data, "supporting an effect of neratinib" while also pointing out that "the tolerability of neratinib in this patient population is a concern."

Image source: Getty Images.

The lack of a negative review is good news for Puma Biotechnology, but given the fairly neutral stance, the committee of outside experts could have a big influence on the FDA's final decision when they meet on Wednesday. The biggest thing for investors to watch is the committee's opinion of the diarrhea side effect and whether the members think treating with an antidiarrheal prophylaxisis an acceptable way to combat it. The doctors' opinions on neratinib relative to other post-surgery treatments will also be important because a negative opinion relative to the other treatments could foretell poor neratinib sales even if the drug is approved.

Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Originally posted here:
Why Puma Biotechnology Inc Jumped Higher Today - Motley Fool

Separation Systems for Commercial Biotechnology Market 2017 … – Business Wire (press release)

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Separation Systems for Commercial Biotechnology" report to their offering.

The market for bioseparation systems is growing rapidly across all regions. Bioseparation purifies biological products on a large-scale. The report focuses on the global market of bioseparation systems and provides an updated review, including basic design and its applications, in various arenas of biomedical and life science research.

The bioseparation techniques that are covered in this report are chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, lab-on-a-chip, biochip, and magnetic separation. Among chromatography techniques, liquid chromatography is the most active market.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the bioseparation systems market. Key players include Thermo Fisher Scientific, Agilent Technologies Inc., Bio-Rad Laboratories, Danaher Corp., Qiagen N.V., Merck KGaA GmbH, and Waters Corp. among others.

Key Topics Covered:

1: Introduction

2: Summary and highlights

3: Overview

- History of biotechnology

- Classification of biomolecular separation systems in biotechnology

- New methods of biomolecular separations

- Molecular classes of biomolecular separation

- End users of biotechnology separation systems

4: New Developments

- Mergers and acquisitions

5: Market Analysis

- Market by type

- Market by region

6: Industry Structure

- Chromatography

- Centrifugation

- Electrophoresis

- Membrane filtration

- Flow cytometry

- Magnetic separation

- Microarrays

- Biochip

- Lab-on-a-chip

7: Patent Analysis

- Patents by year

- Patents by type

- Patents by company

- Patents by country

- Patents by assignee

8: Current Situation

- Factors affecting bioseparation system market

- Market opportunities

9: Company Profiles

- 3M Company

- Abaxis Inc.

- Abtech Scientific Inc.

- Agilent Technologies Inc.

- Alfa Laval Group

- Alfa Wassermann Separation Technologies

- Arrayit Corp.

- BD BioSciences (Becton, Dickinson and Company)

- Biocept Inc.

- Biodot Inc.

- BioMerieux SA

- Bio-Rad Laboratories Inc.

- Boston Microfluidics

- Customarray Inc.

- Danaher Corp.

- DNAmicroarray Inc.

- Falcon Genomics Inc.

- Flottweg Separation Technology

- GE Healthcare Life Sciences

- Hitachi Koki Co. Ltd.

- Illumina Inc.

- Luminex Corp.

- Merck KGaA

- Microarray Inc.

- Nanostring Technologies Inc.

- Novasep Inc.

- PerkinElmer

- Qiagen Gmbh

- Randox Laboratories Ltd.

- Sartorius Corp.

- Shimadzu Scientific Instruments

- Spectrum Chemical Manufacturing Corp.

- Sysmex Partec Gmbh

- Thermo Fisher Scientific

- W. R. Grace & Company

For more information about this report visit http://www.researchandmarkets.com/research/npn5zk/separation

More:
Separation Systems for Commercial Biotechnology Market 2017 ... - Business Wire (press release)

Funding From Alzheimer’s Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials – GlobeNewswire (press release)

April 13, 2017 20:00 ET | Source: M3 Biotechnology

SEATTLE, April 13, 2017 (GLOBE NEWSWIRE) -- As the first investor in M3 Biotechnology, the Alzheimers Drug Discovery Foundation (ADDF) helped validate the therapeutic potential of M3s drug candidate for Alzheimers disease. With a second investment of $1.4 million, the ADDF is now providing key funds to support the launch of human trials this year.

While current drugs for Alzheimers disease only provide symptomatic relief, M3s small molecule therapeutics have the potential to be truly disease-modifying. By re-establishing lost connections between brain cells, these therapies may halt the course of the disease. M3 is now in the process of planning a first-in-humans Phase 1a clinical trial for its lead candidate, NDX-1017, to evaluate its safety and determine optimal dosing range.

ADDFs first investment spurred others, including many private investors and Washington state-based venture groups W Fund and WRF Capital. These investments evidenced the faith in our potential, which helped us make it past the valley of death for drug development and raise nearly $14 million in additional funding, said Leen Kawas, M3s CEO.

The most noteworthy new investor in M3 is Dolby Family Ventures, which invests in technology and life sciences. The fund makes early stage investments in the most promising Alzheimer's-specific therapeutics which require funding for the critical phase of translating successful animal therapies to human clinical trials. The fund honors the late inventor, Ray Dolby, who died in 2013 and who lived with Alzheimer's disease.

The relationship with the ADDF has been vital to our progress as they have fostered a dynamic, collaborative biotech ecosystem, Kawas said. By providing early funding and connecting us with potential partners and investors, the ADDF has helped us reach the clinic.

Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the ADDF, says, We are excited by the promising therapeutic approach of Dr. Kawas and her team at M3 Biotechnology. By helping neurons survive, NDX-1017 may restore cognitive function for Alzheimers patients. The ADDF looks forward to the results from this first human trial.

Alzheimers Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, ADDF is dedicated to accelerating the discovery of drugs to prevent, treat and cure Alzheimers disease. The ADDF is a public charity solely focused on funding the development of drugs for Alzheimers, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, ADDF has awarded over $100 million to fund more than 500 Alzheimers programs in 18 countries.

M3 Biotechnology, Inc. M3 Biotechnology is a therapeutics company with a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases like Alzheimers. M3s lead asset is being advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration. Total financing of $14M to-date is used to prepare for and conduct Phase I clinical trials.

Related Articles

View original post here:
Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials - GlobeNewswire (press release)

Biotechnology: navigating a minefield – Cordis News

When it comes to getting biotechnology innovations to market, with commercial protection, it can be tough. Around three quarters of patent applications normally fail to cut it. Although biotechnology is recognised as being important for the economy and society, it can also be highly controversial attracting public protests

The European Patent Office (EPO) has faced opposition in the past, for instance, over patents relating to processes for re-engineering genes, for use in medical research into cancer treatment. These processes could apply to various animals, including great apes and that became a magnet for criticism from animal rights campaigners.

The number of patent filings for biotechnology increased by 0.3 percent in 2016, to 5,744 making it the tenth largest sector in its field.

Youris.com spoke to Benoit Battistelli, President of the EPO, about the role of patent protection and how it can aid biotechnology innovation and the wider bioeconomy despite the obstacles faced by some.

How much of a focus is the bioeconomy for patents and what are some of the key developments?

Biosciences play an important role in patent applications at the EPO, given the growing convergence of technologies, which is widely responsible for technical progress in a wide number of sectors. Such inventions are mainly found in industrial biotechnology, for instance, in the development of novel products such as new detergents, functional food or even new eco-friendly material in construction, such as pollution-eating concrete and self-healing concrete.

The area of clean energy production is also very important. For example, when it comes to using biomass as an energy source [editors note: In 2011, a Danish inventor won a European Inventor Award organised by the EPO for developing a system which increases the types of biomass fuels that can be used. Typically, biomass materials have to be dried before they can be used as fuel, but Jens Dall Bentzens furnace design can also burn materials with a moisture content of up to 60 percent. Hes since reported to have attracted interest from Europe and the US, selling the furnace to an American manufacturer, as well as building two others for use in Denmark].

Is the bioeconomy an increasing sector?

Biotech is among our top ten technical fields and it has increased. At the end of the patent granting process, its about 50 percent on average that become a patent. Its only 26 or 27 percent in the case of biotech. Why? Because it is a very sensitive issue and we are applying the patentability criteria very rigorously. There are huge European capacities in biotech and we have seen that we must find a good balance between the regulatory constraints and the economic capacities that this sector represents.

The position of the EPO is very clear and simple. There is an EU directive concerning biotech, which we respect and which we have integrated in our own legal framework, the European Patent Convention. Then you have the interpretations of the Directive by the European Court of Justice and we adapt our practice to these judgements.

Overall, how complicated is it to obtain a patent, and is it expensive?

I would not say that it is complicated, but it is a difficult process, because we always start from the basis that a patent is an exception to the principle of free trade, free industry, free competition. Globally, for around 20 to 25,000 euros, you can obtain a patent as the EPO. For this amount, 5,000 euros are the EPO fees and the rest is the fees of those who helped to draft a patent and then discuss it with the patent office.

So, with a patent, you are giving the holder the exclusive right of commercially exploiting his invention, for a certain period of time, a maximum 20 years.

By Damon Embling

See more here:
Biotechnology: navigating a minefield - Cordis News

Separation Systems for Commercial Biotechnology Market 2017 … – Yahoo Finance

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Separation Systems for Commercial Biotechnology" report to their offering.

The market for bioseparation systems is growing rapidly across all regions. Bioseparation purifies biological products on a large-scale. The report focuses on the global market of bioseparation systems and provides an updated review, including basic design and its applications, in various arenas of biomedical and life science research.

The bioseparation techniques that are covered in this report are chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, lab-on-a-chip, biochip, and magnetic separation. Among chromatography techniques, liquid chromatography is the most active market.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the bioseparation systems market. Key players include Thermo Fisher Scientific, Agilent Technologies Inc., Bio-Rad Laboratories, Danaher Corp., Qiagen N.V., Merck KGaA GmbH, and Waters Corp. among others.

Key Topics Covered:

1: Introduction

2: Summary and highlights

3: Overview

- History of biotechnology

- Classification of biomolecular separation systems in biotechnology

- New methods of biomolecular separations

- Molecular classes of biomolecular separation

- End users of biotechnology separation systems

4: New Developments

- Mergers and acquisitions

5: Market Analysis

- Market by type

- Market by region

6: Industry Structure

- Chromatography

- Centrifugation

- Electrophoresis

- Membrane filtration

- Flow cytometry

- Magnetic separation

- Microarrays

- Biochip

- Lab-on-a-chip

7: Patent Analysis

- Patents by year

- Patents by type

- Patents by company

- Patents by country

- Patents by assignee

8: Current Situation

- Factors affecting bioseparation system market

- Market opportunities

9: Company Profiles

- 3M Company

- Abaxis Inc.

- Abtech Scientific Inc.

- Agilent Technologies Inc.

- Alfa Laval Group

- Alfa Wassermann Separation Technologies

- Arrayit Corp.

- BD BioSciences (Becton, Dickinson and Company)

- Biocept Inc.

- Biodot Inc.

- BioMerieux SA

- Bio-Rad Laboratories Inc.

- Boston Microfluidics

- Customarray Inc.

- Danaher Corp.

- DNAmicroarray Inc.

- Falcon Genomics Inc.

- Flottweg Separation Technology

- GE Healthcare Life Sciences

- Hitachi Koki Co. Ltd.

- Illumina Inc.

- Luminex Corp.

- Merck KGaA

- Microarray Inc.

- Nanostring Technologies Inc.

- Novasep Inc.

- PerkinElmer

- Qiagen Gmbh

- Randox Laboratories Ltd.

- Sartorius Corp.

- Shimadzu Scientific Instruments

- Spectrum Chemical Manufacturing Corp.

- Sysmex Partec Gmbh

- Thermo Fisher Scientific

- W. R. Grace & Company

For more information about this report visit http://www.researchandmarkets.com/research/npn5zk/separation

View source version on businesswire.com: http://www.businesswire.com/news/home/20170414005169/en/

See the original post here:
Separation Systems for Commercial Biotechnology Market 2017 ... - Yahoo Finance

Funding From Alzheimer’s Drug Discovery Foundation Advances M3 … – Yahoo Finance

SEATTLE, April 13, 2017 (GLOBE NEWSWIRE) -- As the first investor in M3 Biotechnology, the Alzheimers Drug Discovery Foundation (ADDF) helped validate the therapeutic potential of M3s drug candidate for Alzheimers disease. With a second investment of $1.4 million, the ADDF is now providing key funds to support the launch of human trials this year.

While current drugs for Alzheimers disease only provide symptomatic relief, M3s small molecule therapeutics have the potential to be truly disease-modifying. By re-establishing lost connections between brain cells, these therapies may halt the course of the disease. M3 is now in the process of planning a first-in-humans Phase 1a clinical trial for its lead candidate, NDX-1017, to evaluate its safety and determine optimal dosing range.

ADDFs first investment spurred others, including many private investors and Washington state-based venture groups W Fund and WRF Capital. These investments evidenced the faith in our potential, which helped us make it past the valley of death for drug development and raise nearly $14 million in additional funding, said Leen Kawas, M3s CEO.

The most noteworthy new investor in M3 is Dolby Family Ventures, which invests in technology and life sciences. The fund makes early stage investments in the most promising Alzheimer's-specific therapeutics which require funding for the critical phase of translating successful animal therapies to human clinical trials. The fund honors the late inventor, Ray Dolby, who died in 2013 and who lived with Alzheimer's disease.

The relationship with the ADDF has been vital to our progress as they have fostered a dynamic, collaborative biotech ecosystem, Kawas said. By providing early funding and connecting us with potential partners and investors, the ADDF has helped us reach the clinic.

Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the ADDF, says, We are excited by the promising therapeutic approach of Dr. Kawas and her team at M3 Biotechnology. By helping neurons survive, NDX-1017 may restore cognitive function for Alzheimers patients. The ADDF looks forward to the results from this first human trial.

Alzheimers Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, ADDF is dedicated to accelerating the discovery of drugs to prevent, treat and cure Alzheimers disease. The ADDF is a public charity solely focused on funding the development of drugs for Alzheimers, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, ADDF has awarded over $100 million to fund more than 500 Alzheimers programs in 18 countries.

M3 Biotechnology, Inc. M3 Biotechnology is a therapeutics company with a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases like Alzheimers. M3s lead asset is being advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration. Total financing of $14M to-date is used to prepare for and conduct Phase I clinical trials.

The rest is here:
Funding From Alzheimer's Drug Discovery Foundation Advances M3 ... - Yahoo Finance

Trump Administration should unshackle further innovation in ag biotechnology by rolling back undue regulations – Fence Post

WASHINGTON Overly cautious regulations that contravene decades of academic research and ignore the lessons from massive real-world experience are stifling innovation in plant and animal improvement, said the Information Technology and Innovation Foundation.

The Trump administration should roll back overly precautionary regulations to encourage much-needed innovations that produce safer and more sustainable crops and livestock while still preventing unreasonable risks to public and environmental welfare, argues the science- and tech-policy think tank in a recently released report.

"From reducing the need for pesticides to increasing crop yields, genetically modified crops have already made farming more safe and environmentally friendly," said L. Val Giddings, a senior fellow at ITIF and the report's author. "Researchers are discovering ever more precise, predictable, and easy-to-use techniques derived directly from nature. But despite decades of evidence on the safety of genetically improved crops, unfounded fears and politically driven opposition have led to regulations that chill innovation. It's time to rethink these policies and allow and enable a new generation of discoveries that can feed the world even more safely and sustainably."

Giddings explains that in the 1980s, the U.S. government decided to regulate biotech-improved crops using the same principles and methods it would for any other crops, because expert bodies repeatedly found no unique or novel hazards that made these crops and livestock any different than those derived from the classical plant and animal breeding that has occurred for millennia. But since then, Giddings says the disparity between the minimal risk associated with these innovations and the major regulatory hurdles they must clear has widened from a gap to a chasm.

This discordance between the degree of regulatory oversight and the actual hazards is posing economic and environmental costs, as innovative new products are delayed from reaching the market, Giddings said. To overcome these barriers and unleash a new generation of innovation in agricultural biotechnology, the report recommends that:

The Trump administration should enforce the mandate from the Office of Science and Technology Policy that agencies update their regulations and policies for innovative agricultural-biotechnology products, and that the revised regulations should be effective in preventing unreasonable risks while still encouraging and enabling innovation;

The Animal and Plant Health Inspection Service should set aside its proposal for process-based revisions to existing regulations;

The Food and Drug Administration should enforce the federal law prohibiting misleading food labels;

The FDA should revise its current proposal for regulating gene-edited animals, withdraw its proposal for gene-edited plants, and develop new proposals to exercise its discretion in preventing unreasonable risks;

The Environmental Protection Agency should not prematurely obstruct gene-silencing technologies;

The Fish and Wildlife Service should immediately withdraw the prohibition on planting biotech-improved seeds on national refuge lands; and

The Trump administration should pursue efforts through the World Trade Organization to hold China and the European Union accountable for continuing to discriminate against crops improved through biotechnology, despite being obligated otherwise.

"Biotechnology innovations have improved the lives of farmers around the world, enhanced their stewardship of the land, and benefitted consumers and the environment," Giddings said. "The principle obstacle to even greater and more widespread benefits is regulatory hurdles that aren't grounded in the facts. Setting these barriers aside will unshackle innovators to solve challenges impeding our ability to meet the food, feed and fiber needs of a growing population while reducing undesirable environmental impacts."

Read the full report at http://www2.itif.org/2017-unshackle-agricultural-innovation.pdf?_ga=1.155989245.717142650.1491235245.

Read more:
Trump Administration should unshackle further innovation in ag biotechnology by rolling back undue regulations - Fence Post

Pennsylvania Biotechnology Center begins long-awaited expansion … – Bucks County Courier Times

The Pennsylvania Biotechnology Center on Wednesday broke ground on a long-awaited expansion that will add laboratories, office space and at least 100 new jobs to its campus in Buckingham.

"This has become a real state resource," said biotechnology center President Timothy Block. "We can't exist in these two buildings anymore. We need to grow."

Created more than 10 years ago through a partnership between the Hepatitis B Foundation and Delaware Valley University, the Biotechnology Center has grown to become an economic powerhouse in the region, contributing an estimated $1.8 billion to the local economy and supporting more than 700 jobs, half of those within the center itself.

Because of the center's success, it's been a draw for scientists and entrepreneurs throughout the region. Lab space is at a premium, and there's a waiting list for tenants. The new wing is already 40 percent leased, Block said.

The first tenant, contract research organization FlowMetric Inc., credits the center with its growth. The company now has three dozen employees.

"I could have set up my company in New Jersey. But there was no place that was quite like this, and that has continued for us," said CEO Ren Capocasale.

"This center is why I do what I do."

While construction likely won't begin until the summer, biotech center officials chose Wednesday for the ceremonial groundbreaking in part because it also happened to be the 96th birthday of Joshua Feldstein, a longtime supporter for whom a wing of the center is named.

Feldstein was on hand for Wednesday's event, seated among a variety of state and local dignitaries that included state Rep. Marguerite Quinn, R-143, Doylestown, and state Sen. Chuck McIlhinney, R-10, Doylestown both longtime supporters of the center and Congressman Brian Fitzpatrick, R-8, Middletown.

"This is not a Republican or Democrat thing," said Quinn. "We've had support from both sides of the aisle, recognizing what you do here: jobs, cures and research. Well-paying jobs and phenomenal research."

First proposed in 2015, the expansion project stalled during a dispute between the Hepatitis B Foundation and Delaware Valley University. Unhappy with how the foundation was running the center's day-to-day operations, the university refused to sign off on the expansion plans.

The dispute ended in October, when the Hepatitis B Foundation agreed to pay $2 million to buy DelVal's interests in the center.

The final project will cost between $12 million and $13 million, center officials said. That will be offset by a $4.6 million grant from the federal government and a $2 million state grant. The rest will be financed with a conventional loan awarded by Univest Bank.

Officials on Wednesday, however, weren't just celebrating the expansion. They were thinking about the future.

"We need to be thinking about what the next thing we're going to put the shovel in the ground (for) here with what's happening here," said Bucks County Commissioner Rob Loughery.

Block envisions a biotechnology hub within Bucks County one that equals the well-known Kendall Square area of Boston.

"There is a resource in Bucks County as vital and powerful, with as much potential, as the shale under the earth here," Block said. "That's what we're going to tap into."

The rest is here:
Pennsylvania Biotechnology Center begins long-awaited expansion ... - Bucks County Courier Times

Biotechnology Education vs Industry Requirements: Where – BSI bureau (press release)

Dr Vinay Rale shares his thoughts with BioSpectrum on current biotech education and the academia-industry gap

Dr Vinay Rale, Director, Symbiosis School of Biomedical Sciences (SSBS)

Brief recapitulation of genesis of Biotechnology in India A quick recapitulation of the genesis of Biotechnology in India will not be out of place to apprise the lay public. We essentially (and blindly) followed the USA in 1985 in initiating Biotechnology programs at Master's level at six select universities across India. In the 1970s, the ability to modify DNA molecules and the realization of the power of genetic engineering led prominent universities in the US to convince their Government to allocate huge funds to start

Biotechnology' - a term newly coined by them. The Indian model, first at Masters level, to cater to the need for trained manpower for the anticipated boom in the Biotechnology industry was supported by the Department of Biotechnology (DBT). Very soon a large number of institutions both in private and public sector followed suit to attract students. The wildfire spread to undergraduate programs equally rapidly. However, this led to two major disadvantages - the relegation of basic courses in Life Sciences such as Microbiology, Biochemistry, Zoology and Botany and severely inadequate infrastructure and untrained faculty. As a matter of fact, the first Masters programs supported by DBT at six prominent institutions in the country were turned to the advantage of the then faculty expertise, e.g., developmental biology turning a blind eye to the basic essentials that the students have to be proficient in.

A rough estimate of the students enrolled in Biotechnology at undergraduate and postgraduate levels suggests a number exceeding 100,000 at any given time. Also, some institutions offer a bouquet of 8 to 9 allied courses in Biotechnology. Naturally the demand-supply ratio is skewed. The curricula in Biotechnology tries to accommodate' as many subsets as possible with little attention to the fundamentals - especially at the undergraduate levels. Moreover, to overcome the infrastructure deficiency, a good number of students (especially at postgraduate level) are encouraged to bank upon either research institutes or industries to undertake dissertations.

Unfortunately, both categories of organizations take little interest in the welfare of such dissertation research; more so due to the unavailability of mentors from either side. Therefore-, little research done at such levels goes unnoticed. As a consequence-, it is estimated that well over 70 percent of Biotechnology students are considered as unemployable by industries. This is the net result of a large number of factors contributing to the creation of unfit student mass. Reliable sources indicate that industries now prefer to hire students trained in conventional Life Sciences like Microbiology and Biochemistry (also Chemistry) to meet their stringent requirements. The general complaint is that the Biotechnology students lack fundamentals. This is also the observation of this author over the decades.

Considering the seriousness of the Government to increase funding for the DBT and the intiative of the Biotechnology Industry Research Assistance Council (BIRAC) coupled with those of SIDBI and MSME to strengthen research in academia and foster strategic alliances between academia and industry, one can only expect better things to happen. However, like Biotechnology, Microbiology and Biochemistry programs too need nourishment.

Read the rest here:
Biotechnology Education vs Industry Requirements: Where - BSI bureau (press release)

iShares NASDAQ Biotechnology Index (IBB) Plans Quarterly Dividend of $0.30 – The Cerbat Gem

iShares NASDAQ Biotechnology Index (IBB) Plans Quarterly Dividend of $0.30
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo iShares NASDAQ Biotechnology Index (NASDAQ:IBB) declared a quarterly dividend on Friday, March 24th. Stockholders of record on Tuesday, March 28th will be given a dividend of 0.299 per share on Thursday, ...
iShares NASDAQ Biotechnology Index (IBB) Upgraded to "Buy" by Vetr Inc.BBNS

all 11 news articles »

Go here to see the original:
iShares NASDAQ Biotechnology Index (IBB) Plans Quarterly Dividend of $0.30 - The Cerbat Gem

Expert: Biotechnology will aid sustainable agricultural production – P.M. News

Biotech

Prof. Benjamin Ubi, the President, (BSN), says the adoption of biotechnology will facilitate sustainable agricultural production in the country.

Ubi made the declaration in an interview with News Agency of Nigeria (NAN) in Abuja on Thursday

He said that the adoption of biotechnology applications was the panacea to the current food challenges facing the country.

Biotechnology, including genetic engineering and production of Genetically Modified Organisms (GMOs), provides powerful tools for the sustainable development of agriculture, fishery and forestry, as well as meeting the food needs of the population.

GMOs currently account for about 16 per cent of the worlds crops, particularly crops like soybean, maize, cotton and canola, and there are indications that the growing trend will continue.

So, we must eat what we grow and grow what we eat. This means we ought to produce more and agricultural biotechnology is a tool for achieving this, he said.

Ubi also pledged the support of the BSN for the efforts of National Biosafety Management Agency (NBMA) to harness the potential of modern biotechnology.

READ: Kwara International Vocational Centre gets equipment

BSN, as a stakeholder in biosafety, will continue to support NBMA; we should all be rest assured that no biotechnology product will be imposed on anyone.

Hunger and peace work hand-in-hand, so lack of hunger consequently promotes peace; therefore, biotechnology and its derivatives should be adopted for the benefit of Nigerians, while maintaining regulatory standards.

Biotechnology and biosafety stakeholders must, therefore, work in tandem with global bodies because Nigeria is not a pariah nation; we are a responsible and respected member of the global community, he said.

Ubi urged anti-GMO campaigners not to play politics with issues that could engender food security and alleviate poverty, saying that tangible efforts should be made to enhance the availability and affordability of high-quality foods via biotechnology applications.

I assure all that modern biotechnology had been found to be safe by global certification bodies.

All the same, informed criticism is good for checks and balances but it should not be allowed to be a clog the wheel of progress, he added.

See original here:
Expert: Biotechnology will aid sustainable agricultural production - P.M. News

Vir Biotechnology Up; to Work With Biogen on Antibodies to Potentially Treat Covid-19 – Morningstar.com

By Michael Dabaie

Vir Biotechnology Inc. shares were up 10% to $37.06 in heavier-than-average volume.

Before the market open, the company said it signed a letter of intent to collaborate with Biogen Inc. on manufacturing of antibodies to potentially treat Covid-19.

Vir said that because of the urgency of the situation, the companies have begun work while a clinical development and manufacturing agreement is being negotiated.

Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Vir's proprietary antibodies.

Vir said it has identified monoclonal antibodies that bind to SARS-CoV-2, which were isolated from individuals who had survived a severe acute respiratory syndrome infection. The company said it is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and prophylaxis against SARS-CoV-2.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

March 12, 2020 12:48 ET (16:48 GMT)

Excerpt from:
Vir Biotechnology Up; to Work With Biogen on Antibodies to Potentially Treat Covid-19 - Morningstar.com

Nanoparticles in Biotechnology and Pharmaceuticals Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Bandera County…

Verified Market Research recently published a research report titled, Nanoparticles in Biotechnology and Pharmaceuticals Market Study Report 2020. The research report is created based on historical and forecast data derived from researchers using primary and secondary methods. The Nanoparticles in Biotechnology and Pharmaceuticals market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The report clearly explains the trajectory this market will take in the forecast years.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=BCC&utm_medium=002

Nanoparticles in Biotechnology and Pharmaceuticals Market Leading Players:

Nanoparticles in Biotechnology and Pharmaceuticals Market: Competitive Landscape

This section of the report provides complete information about the various manufacturers in the market. The major manufacturers to which the report refers hold a large proportion that require a microscopic appearance. It provides important information about the different strategies of these manufacturers to combat competition and to expand their presence in the market. In addition, the current trends of the manufacturers are checked in order to innovate their product for the future. This report is intended to help the reader understand the market and make business decisions accordingly.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=BCC&utm_medium=002

Table of Contents :

Executive Summary: It includes key trends of the Nanoparticles in Biotechnology and Pharmaceuticals market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Nanoparticles in Biotechnology and Pharmaceuticals market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Nanoparticles in Biotechnology and Pharmaceuticals market.

Market Segments: This part of the report discusses about product type and application segments of the Nanoparticles in Biotechnology and Pharmaceuticals market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the Nanoparticles in Biotechnology and Pharmaceuticals market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the Nanoparticles in Biotechnology and Pharmaceuticals market.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=BCC&utm_medium=002

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: sales@verifiedmarketresearch.com

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Go here to read the rest:
Nanoparticles in Biotechnology and Pharmaceuticals Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Bandera County...

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses…

Joint research project to include SARS-CoV-2

SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc.(VIR) today announced a research collaboration agreement with the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC) to advance characterization and development of human monoclonal antibodies (mAbs) against coronaviruses, including SARS-CoV-2, the virus that causes the disease COVID-19. The joint project, which will begin this week, will augment ongoing efforts by both parties to identify antibodies that can be used to prevent or treat infection with existing and emerging viruses and help inform the development of vaccines.

Under the terms of the agreement, Vir and NIAID will work together to identify and optimize combinations of antibodies against coronaviruses, including SARS-CoV-2, SARS and MERS, as well as antibodies that may be effective across additional types of coronaviruses. The two parties will exchange antibodies and other materials for testing in combination and individually and, by mutual agreement, will perform in vivo animal studies to analyze immune responses.

This collaboration expands Virs efforts to characterize and develop antibody therapies against coronaviruses by allowing us to access the VRCs significant and broad research experience with coronaviruses, which is complementary to ours, said Herbert Skip Virgin, M.D., Ph.D., Chief Scientific Officer, Vir. This is one of multiple approaches we are taking to rapidly identify and test potential prophylactics and therapeutics for COVID-19 and we expect it to allow us to accelerate finding solutions to this urgent public health need.

Vir has identified a number of monoclonal antibodies that bind to SARS-CoV-2. These antibodies were isolated from individuals who had survived a SARS infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify from COVID-19 survivors, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

NIAID-funded scientists are exploring ways to treat and prevent human coronavirus infections by working to develop new antibodies, drugs, and vaccines that block entry to cells, enhance the immune system response, or block viral replication. To date, this research has focused on the coronavirus spike protein and includes development of neutralization assays and competition assays that are used to characterize antibodies.

About Virs Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in theDemocratic Republic of Congo), hepatitis B virus, influenza A, malaria, and others.

AboutVir Biotechnology

Vir Biotechnologyis a clinical-stage immunology company focused on treating and preventing serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend, potential and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the companys efforts to neutralize the SARS-CoV-2 virus and identify additional potential therapies for SARS-CoV-2, and its ability to address the emerging public health epidemic. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in neutralizing SARS-CoV-2, difficulty in collaborating with other companies or government agencies, and challenges in accessing manufacturing capacity. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with theU.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Story continues

Contact:Vir Biotechnology, Inc.

Investors Neera Ravindran, MDHead of Investor Relations & Strategic Communications nravindran@vir.bio+1-415-506-5256

Media Lindy Devereux Scient PR lindy@scientpr.com +1-646-515-5730

Read the original post:
Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses...

Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? – Genetic Literacy Project

In 1923,Frank Silver and Irving Cohn publisheda song that became a major hitfor the Billy Jones Orchestra, with thesignature line Yes, we have no bananas; we have no bananas today. It turned out to be sadly prophetic as, in the 1950s, the banana trees that supplied the entire global banana export business were wiped out by a soil-borne fungal diseaseknown asPanama Wilt.

The industry at that time was almost entirely based on a single banana cultivar called Gros Michel (meaning Big Mike), and it was susceptible to infection by a strain of fungus called Fusarium. Once the soil of a given plantation was contaminated with that strain, any Gros Michel tree grown there would soon die.

By good fortune, a different banana cultivar that was being grown in the South Seas was able to substitute for Gros Michel as a commercial line, and this new Cavendish cultivar became the new banana of international commerce, as it remains to this day. (Check out this interesting blog post about the history of the Cavendish variety and how it actually passed through a greenhouse in England in that process! And here is another good post about the history of this disease and the industry.)

Unfortunately, its about time for some band to cover Yes, We Have No Bananas because, evolution being what it is, a new strain of Fusarium Tropical Race 4 has arisen and it is lethal to the Cavendish. The disease is slowly making its way around the world, and since it can be spread in a particle of dirt on something like a boot, it will almost inevitably make it to the Central and South American growing regions that supply both North America and Europe with their bananas.

Although this unfortunate scenario has been on the minds of the banana industry for decades, it is now starting to get more attention in the mainstream press. One part of the story that has been shocking to these outside observers is that such a huge industry would ever be dependent on a single cultivar of banana. As Stephen Mihm put it for Bloomberg, this looming bananapocalypse is attributable to a vulnerability that comes from the practice of extreme monoculture.

While I understand why observers might be shocked that a nearly $12 billion industry depends almost exclusively on the Cavendish banana, I do want to push back on the implied conclusion that this represents some sort of irrational or irresponsible expression of big ag or whatever other demons are imagined by the Food Movement.

When you see something that is a standard practice in a very large, nationally diverse and multi-company business like bananas, I would suggest that it is appropriate to ask not what is wrong with this system but rather, What are the practical factors that drive this seemingly irrational practice?

Im not a banana expert, but in the mid-1990s, two of my first jobs as an independent consultant had to do with the banana industry. It was during the exciting early years of commercial plant biotechnology, and many industries were asking, What might this new technology do for our business? Both of my projects involved early-stage discussions between a major banana company and a plant biotech company four different entities in all. These were drawing board stage projects, with the goal of figuring out if certain ideas could ever make economic sense: Would they be something worth years of effort and millions of dollars for research?Still, overall, biotechnology looked like a way for this industry to tap into genetic diversity.

The fun part for me was getting to do a deep dive into the details of how bananas are grown, handled, shipped and marketed. I got to travel to Honduras, Costa Rica and Ecuador to tour banana plantations and interact with experts at the major banana export companies. As I said, Im not an industry insider, but I think I can shed some light on why there are not more kinds of bananas grown for export.

As modern consumers, we are offered an amazingly diverse selection of fresh fruits and vegetables year-round, so it is important to think back to the early days of this offer of plenty. Having grownup in Denver in the 1960s, I can recall that, except for a few summer months, almost the only fresh fruit options at the grocery store were bananas, apples and oranges. I have a podcast aboutwhy apples were ever on that list. But if you think about it, the very fact that we can so easily enjoy fresh bananas in temperate regionsis a bit remarkable.

Bananas can grow only in regions where there is never frost, and they do best in truly tropical climates. How did a tropical fruit become a mainstream, reasonably priced, healthful, kid-popular fruit for people who experience winter?

In tropical regions, there is a great deal of genetic diversity among wild bananas and considerable diversity among the banana or plantain types that humans cultivate. However, very few of these bananas could ever meet the criteria needed to be a viable export crop.

First of all, a banana for export has to be seedless. Many wild bananas have large, very hard black seeds not something that has much consumer appeal. The bananas that people like are seedless because they have triploid genetics three of each chromosome vs. the two that we have. That is the same way we get seedless watermelons, grapes, etc. Its not some GMO thing; it happens at times in the plant kingdom, and we humans like it! Still, improving or changing the cultivar through conventional breeding isnt an option if it makes no seeds.

Next, the banana needs to be productive in terms of overall yield per tree or acre. Im sure no one in the 1920s was calculating it, but in modern sustainability thinking, the land-use efficiency of a crop is an important criterion. That, along with water-use efficiency, small carbon footprint and energy footprint,is all very much tied to good yield. The usable per-hectare yields of the Cavendish variety are quite high, and that is why it has been a both economically viable and environmentally sustainable choice for a long time.

But probably the most limiting requirement for a banana variety to be commercially acceptable is thatit has to be shippable. In the modern era, we have lots of transport options for food products, but during the era when the banana was becoming an item of international trade, the only viable option was ocean shipping. A product being moved from the tropics to North America or Europe needed a very-low-cost transport option if it was ever going to be a mainstream consumer product. Most fresh produce products loaded onto a ship for a two-plus-week trip to a northern port would be a soup of decay by the time they arrived.

What made the Gros Michel and its successor, the Cavendish, remarkable was that they could make that trip at a temperature range of 55-58 degrees Fahrenheit, and so not even require lots of energy for refrigeration. Very few of the wonderful range of cultivated or wild banana types could ever do that, but because the Cavendish can be shipped this way, the energy and carbon footprint ofits shipment is small. This crop has a very attractive food-miles profile.

In addition,it turns out that the conditions under which bananas grow can affect their shipping potential. There is a disease that infects only the leaves of banana plants called Black Sigatoka. If a banana tree has suffered too much of that infection, even the robust Cavendish variety wont be able to make the trip by sea. One thing I learned on my tour was that plantations have employees whose whole job is to survey the plantation on a tree-by-tree basis in order to qualify the fruit for shipment based on how well that disease has been managed.

But it gets even more complicated than that (heres a good video summary of the process). Bananas are picked in Central and South America at a green stage imagine a fruit more completely green than the greenest one youve ever seen in the clusters in your store. When they get to their destination, they are put into ripening rooms, where they are exposed to ethylene gas to start them on the way to the ripe yellow fruit you know. Before you freak out, know that ethylene is the fully natural plant hormone that induces ripening in most fruits and vegetables.

There is a definite art to this ripening process, and highly valued experts who can assess each shipment of bananas know just how to handle them in the ripening rooms to achieve the goal of delivering just right bananas at retail. This process has to factor in issues like ups and downs in demand and turnover rates at key retail customer outlets, in addition to the condition of the incoming fruit.

I know that at the stores where I shop, I can consistently buy bananas that are close to ripe but not fully, such that I can hope to consume them all before they turn black. We consumers might think we have a balancing act to do when it comes to timing ripening and consumption of the bananas from our counters, but imagine that on a huge scale for the banana distribution chain.

There is one more critical element of the business model: Those ships that come to our ports loaded with bananas certainly cant go back empty. The banana shipping companies are also seriously involved in their back-haul business of bringing back products of interest in the source countries. Having a well-understood, predictable crop helps with running that business efficiently as well.

So for the international banana business to work in a way that provides a relatively low-cost product acceptable to consumers, it needs to be able to function in a reliable and predictable fashion. Figuring out how to do this with a new banana variety would be a huge challenge. How do you grow it efficiently? Can the crop make the trip reliably? How can its ripeness be managed in order to meet both the distribution chain requirements and the needs of consumers for decent counter life? Will all of this work in a way that is compatible with a viable back-haul business?

So while it is easy to think that the banana industry is crazy to depend on one cultivar, Isubmit to you thatit is not without reasonand it implies noirresponsibility.

So does that just mean that we are inevitably going to live out the unintended prophecy of yes, we have no bananas? I think that depends on whether we continue to live in a world where anti-biotechnology groups are able to exercise the control that they currently have over our food system.

Let me explain. Remember that my introduction to bananas was based on excitement about what biotechnology could do for the crop. One of the concepts was to develop bananas that were resistant to that leaf infection disease that can compromise ship-ability. Control of that disease requires something like 40 fungicide sprays a year, so as you can imagine, there would be a huge cost savings if the trees could be made resistant.

The other concept on the table was modifying the banana so that it would stay in that nice yellow, but not yet black, stage longer on the consumers counter. Ill never forget that in the first meeting about that idea, a participant who worked for a UK-based banana importer said in his very British accent: Why would you want to do that? Dont you know that the dustbin is a major consumer of bananas? Obviously, he wasnt attuned to current sensitivity to the need for food waste reduction. I thought it was cool that a banana company was serious about an idea that might reduce food waste, with the hope that it would make consumers more comfortable about buying even more bananas.

Well, these were just theoretical ideas at the time, and they didnt go anywhere because it soon became evident that the anti-GMO forces were quite successful at putting brand-sensitive companies in an untenable spot if they were using GMO crops not just for generic ingredients but for brand-central crops.A dramatic examplewas how fast-food chains like McDonalds moved to avoid biotech potatoes for their signature fries.

It quickly became clear to the banana companies that their brands and their retail store access could be compromised if they pursued GMO options. The irony here is that this would have been the most viable strategy with which to bring genetic diversity into the logical but extreme monoculture of bananas.

Sothe irony is that if the yes, we have no bananas scenario becomes a reality, it will be because we as a global society didnt use a safe, viable, scientifically sound strategy torationally deal with the problem in the banana crop.

Public institution scientists in Australiaand entrepreneurial scientists in Latin America have come up with ways to modify commercially relevant bananas to resist the Fusarium disease. Ideally, there would be the potential to use several approaches, either in the same banana or in different fields; that wouldavoid delay selection for resistance and avoid yet another dependency on a single line. It is likely that the heritage variety Gros Michel could be made commercially viable once again!

If the Fusarium-resistant biotech bananas were introduced, activists would almost certainly attack them as GMO.Would any of the big banana companies have the guts to move forward with the technology in spite of the inevitable brand attacks by NGOs?Would any big food retailers be willing to resist the inevitable pressures not to stock that fruit? That retail blockage strategy is being used today against other new biotech offerings such asnon-browning applesandpotatoesandfast-growing, terrestrially raised salmon.

At one level, this is a question about what will be available for us as consumers. Will we continue to have this highly consumed, reasonably priced, child-friendly, healthy food option? Maybe not. But there is another big question.

One thing I witnessed on those visits to the banana industry back in the 90s was that large communities in Central and South America flourish because of the jobs that this industry creates. We in the rich world will still have lots of other fruit choices if the stores have no bananas, but that flexibility isnt there for the familiesthat have been doing the work to provide us with this staple food option for so many decades.

I would think that most activists are the kind of people who care about the availability of healthy, low-cost fruit options; I doubt that they would want to see the banana-producing communities impoverished. However, if the current paradigm of anti-GMO intimidation of fruit companies and retailers continues, that is where we are headed.

A version of this story originally ran on the GLP on April 16, 2018.

Steve Savage is a plant pathologist and senior contributor to the GLP. His Pop Agriculture podcast is available for listening or subscription on iTunes and Google Podcasts. Follow him on Twitter @grapedoc

See the original post:
Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? - Genetic Literacy Project

Polymerase Chain Reaction (PCR) Market: Pharmaceutical & Biotechnology Industry Segment Held a Major Share of the Global Market – BioSpace

Rising at an impressive single digit CAGR, the global polymerase chain reaction market is predicted to attain a value of almost US$7.0 bn by 2026-end. Factors enabling the market to rise so impressively is the increasing research and development expenditure, gigantic strides made in the domain of pharmacogenomics, and rising trend of self-diagnosis of ailments. The global polymerase chain reaction (PCR) market is also being boosted by new technologies for diagnosis of cancer.

Further, research and development in advanced molecular biology, forensic science, and genetic engineering are also predicted to positively influence the global polymerase chain reaction (PCR) market. The only hurdle emergence of the alternative next-generation sequencing. The expensiveness of certain commercial PCR technologies is also dampening sales in the market to a degree.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=830

A few noticeable trends which key stakeholders in the global polymerase chain reaction (PCR) market need to keep in mind are as follows:

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough, Request for Custom Research at https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=830

Pharmaceutical & Biotechnology Industry Segment Held a Major Share of the Global PCR Market in 2017

The PCR technique has been found to be useful in pharmaceutical and biotechnology research activities as well as microbial quality testing. The technique is also applied in genetic engineering. Genetic engineering is the key driver for the global PCR market. It is used to identify genes related to certain phenotypes including genetic disorders. Regular testing of the microbial load of raw materials and finished products is an important process in the pharmaceutical & biotechnology industry. Sophisticated analytical methods such as polymerase chain reaction (PCR) have been widely applied for quality control analysis in the pharmaceutical sector.

Market in Asia Pacific to Expand at a High CAGR

Molecular diagnosis has revolutionized the modern diagnosis technology. PCR has become a method of choice in early and accurate detection of diseases. Expansion by leading manufacturers of PCR products in the Asia Pacific region by strengthening of the distribution network and new product launches in developing countries of Asia Pacific are key factors likely to drive the PCR market in the region during the forecast period.

Moreover, rise in the incidence of cancer and infectious diseases has resulted in increase in the demand for use of the PCR technique in clinical diagnosis of these diseases in Asia Pacific. For instance, according to the Korea Central Cancer Registry published in 2016, there were 217,057 cancer cases in South Korea in 2014. Moreover, in 2016, the WHO estimated that the Asia Pacific region has the second-highest number (i.e. 5.1 million) of people living with HIV across the world. Thus, Asia Pacific is expected to be the most lucrative market for PCR by 2026.

Buy Polymerase Chain Reaction (PCR) Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=830&ltype=S

Competition Landscape

Major players operating in the global PCR market are Bio-Rad Laboratories, Inc., QIAGEN N.V., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc. Becton, Dickinson and Company, Abbott, Siemens Healthcare GmbH (Siemens AG), bioMrieux SA, Danaher Corporation, and Agilent Technologies. Key players are expanding their product portfolio through mergers and acquisitions and partnerships and collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.

More Trending Reports by Transparency Market Research -

Life Science Instrumentation Market: The global life science instrumentation market is projected to reach US$ 90 Bn by 2027, expanding at a single digit CAGR during the forecast period. Rise in prevalence and incidence rates of infectious diseases, high R&D investment by major players, and technological advancements are anticipated to drive the global market during the forecast period.

Molecular Diagnostic Market: Molecular diagnostics uses techniques such as nucleic acid amplification and hybridization for identification of microorganisms and presence of virulence factors. Various molecular assays have been developed using various technologies. These technologies increased the accuracy of the tests, producing rapid results.

Oligonucleotide Synthesis Market: According to the report by Transparency Market Research, the oligonucleotide synthesis market stood at US$1.65 bn in 2016 and is projected to reach a value of US$4.189 bn by the end of 2025. The market is likely to expand with a stellar CAGR of 11.2% over the forecast period from 2017 and 2025.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Original post:
Polymerase Chain Reaction (PCR) Market: Pharmaceutical & Biotechnology Industry Segment Held a Major Share of the Global Market - BioSpace

Cuba’s revolutionary cancer vaccine builds bridges between the island and the United States – AL DIA News

Despite the fact that Donald Trump's government is determined to continue sanctioning Cuba - the charter flights from the U.S. to nine Cuban airports were suspended last week because of the country's support for Maduro's regime, according to statements by Secretary of State Mike Pompeo - the collaboration between the United States and the island continues, at least on scientific matters. And this should not surprise us, taking into account the great medical advances made by Cuban professionals in the treatment of various types of cancer.

This is what we'll be able to witness in "Cuba's Cancer Hope," a documentary by Llew Smith that will be released next April by PBS and that sheds light on CimaVax, a revolutionary treatment against lung cancer that prolongs the life of patients in very advanced stages and that the Center of Molecular Immunology (CIM) in Habana has taken more than twenty years to develop.

In fact, the results are so encouraging that the Roswell Park Comprehensive Cancer Center in New York soon joined the project and will be the first U.S. institution to conduct a clinical trial of the drug produced on the island.

"The future of our country must necessarily be a future of men of science and thought, because that is precisely what we are sowing most," Fidel Castro, 1960.

Llew Smith himself was one of the volunteers to test this pioneering treatment, according to Prensa Latina, and his results, which were made known two years ago, will be part of the documentary.

"The wonderful thing about working with our Cuban colleagues is that they really believe, in their heart of hearts, that medical care is a human right," said Dr. Kevin Lee, director of the Roswell Park immunology department, in a dialogue with the press, praising the medical advances being made in Cuba and its "great potential to treat and prevent cancer of various kinds."

Cuba a pioneer in science

Biotechnology is one of the most developed branches of Cuban science, which began to be promoted in 1980, when Fidel Castro's government created a group dedicated to the production of interphenon, a possible cancer drug, in addition to promoting scientific parks.

This is a commitment to progress that the current president of Cuba, Miguel Daz-Canel Bermdez, acknowledged to Castro on the occasion of the documentary, and which the late revolutionary leader already advocated in a speech made in 1960when he said:

"The future of our country must necessarily be a future of men of science and thoughtbecause that is precisely what we are sowing most."

But the CimaVax is not the only discovery of Cuban scientists, whose achievements can be traced in the history of the island:

In 1881, the scientist Carlos Juan Finlay was the discoverer of the agent that transmits yellow fever, the Aedes aegypti mosquito, which made it possible to clean up the areas invaded by this infectious agent and which, in the end, has prevented millions of deaths.

"The wonderful thing about working with our Cuban colleagues is that they truly believe, deep in their hearts, that medical care is a human right," Dr. Kevin Lee from Roswell Park.

Also at Cuba's Center for Genetic Engineering and Biotechnology (CIGB), Heberprot-P was developed, a unique drug that prevents the amputation of diabetic feet by healing ulcers.

In addition, Cuba was recognized by WHO as the first country in the world to eliminate mother-to-child transmission of HIV.

The documentary "Cuba's Cancer Hope" also includes other therapies being experimented with on the island, specifically for the treatment of different types of cancer, which once again confirms thatscientific advances are breaking down the walls that apparently separate us.

Read the original here:
Cuba's revolutionary cancer vaccine builds bridges between the island and the United States - AL DIA News

Critical Analysis: PDS Biotechnology (NASDAQ:PDSB) and Merus (NASDAQ:MRUS) – Riverton Roll

Merus (NASDAQ:MRUS) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Institutional & Insider Ownership

50.8% of Merus shares are owned by institutional investors. Comparatively, 8.8% of PDS Biotechnology shares are owned by institutional investors. 43.9% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Merus and PDS Biotechnology, as reported by MarketBeat.

Merus currently has a consensus price target of $24.00, suggesting a potential upside of 77.51%. PDS Biotechnology has a consensus price target of $8.50, suggesting a potential upside of 235.97%. Given PDS Biotechnologys stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Merus.

Profitability

This table compares Merus and PDS Biotechnologys net margins, return on equity and return on assets.

Volatility & Risk

Merus has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.

Earnings and Valuation

This table compares Merus and PDS Biotechnologys gross revenue, earnings per share and valuation.

Merus has higher revenue and earnings than PDS Biotechnology. Merus is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Summary

Merus beats PDS Biotechnology on 7 of the 12 factors compared between the two stocks.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its lead product candidate is PDS0101, a monotherapy first line therapy for cervical intraepithelial neoplasia of cancer. In addition, the company develops PDS0102, which is in phase 2 clinical trial for treatment of prostate and breast cancers. Further, its pipeline product portfolio includes PDS0103 for treatment of colorectal, breast, ovarian, and lung cancers; and PDS 0104 for treatment of melanoma. Additionally, the company offers Versamune, a T-cell activating platform developed for immunotherapy approaches, such as checkpoint inhibitors, CAR-T cells and live-vector based vaccines, etc. The company has collaboration agreement with Merck and Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer. PDS Biotechnology Corporation was incorporated in 2009 and is based in Berkeley Heights, New Jersey.

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.

View post:
Critical Analysis: PDS Biotechnology (NASDAQ:PDSB) and Merus (NASDAQ:MRUS) - Riverton Roll